ImmunityBio’s Legal and Commercial Timelines Diverge Under Scrutiny

ImmunityBio finds itself navigating a stark contradiction. While its commercial engine is firing on all cylinders, a brewing legal storm threatens to overshadow its record-breaking financial performance. The biotech firm is caught between surging revenue from its flagship cancer drug and a class-action lawsuit stemming from regulatory missteps.

The company reported preliminary net product revenue of approximately $44.2 million for the first quarter of 2026, a staggering 168% increase year-over-year. Sequentially, sales grew by 15%. This operational strength is underscored by a solid balance sheet, with cash, cash equivalents, and marketable securities totaling nearly $381 million as of quarter-end. An additional $75 million in non-dilutive financing from Oberland Capital further bolsters its financial position.

This impressive growth is driven by Anktiva, the company’s bladder cancer therapy. The drug is now approved across five regulatory jurisdictions, covering approximately 34 countries. In March, ImmunityBio submitted a supplemental Biologics License Application (sBLA) to the FDA for Anktiva in combination with BCG for an additional bladder cancer indication. The agency accepted the filing without requiring new clinical trials.

However, a significant legal overhang persists. The catalyst was an FDA warning letter, dated March 13 and made public on March 24, 2026. The agency alleged that promotional communications, including a TV commercial and a podcast appearance, misrepresented Anktiva’s capabilities. In the podcast titled “Is the FDA BLOCKING Life Saving Cancer Treatments?” which aired on January 19, Executive Chairman Patrick Soon-Shiong stated the drug, while approved for bladder cancer, could “actually treat all cancers.” The FDA classified this as promotional speech, a claim Soon-Shiong contests, arguing his comments were scientific in nature.

The market’s reaction was severe. On March 24, ImmunityBio’s stock price plummeted roughly 21%, falling from $9.40 to $7.41. This single-day sell-off wiped nearly $2 billion from the company’s market capitalization.

Should investors sell immediately? Or is it worth buying ImmunityBio?

In response to the FDA, the company filed a comprehensive formal response on April 6. It removed the podcast from its website and stated the TV commercial had never aired. ImmunityBio also announced enhanced compliance measures, including stricter promotional review processes and external oversight.

The legal fallout was swift. Law firms including Kessler Topaz Meltzer & Check and the Rosen Law Firm filed class-action complaints on April 19, 2026. The suits, targeting statements made between January 19 and March 24, allege the company overstated Anktiva’s potential, misleading investors. The deadline for investors to file a motion to be appointed lead plaintiff in the central California district court is May 26, 2026. This date represents the next critical milestone, potentially determining the scale of the ongoing legal challenge.

The situation is compounded by prior FDA communications. The agency had sent Untitled Letters to Altor BioScience, an ImmunityBio subsidiary, in September 2025 and January 2026 regarding similar violations, yet the promotional activities continued.

ImmunityBio now operates on two parallel tracks: one of robust commercial expansion and another of legal and regulatory remediation. The coming weeks will reveal whether its operational momentum can ultimately outweigh the persistent weight of litigation.